BEYONDSPRING INC

BYSINASDAQ

🏆 #3977 by market capEarnings Aug 12US Equity

$0.80▲ $0.01 (+0.88%)

Live

1h—

24h▲ 0.9%

7d▼ 19.9%

14d▼ 31.3%

30d▼ 39.2%

1y▼ 60.4%

🏦Market Cap

$33M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

23.9x

Expensive

Otter Score

Fair

Trading Snapshot

Day Range: $0.78 – $0.80
52-Week Range: $0.76 – $2.44
Volume: $3.73B
Avg Volume: $4.29B
Shares Outstanding: 41.1M
Next Earnings: Oct 28, 2026

Fundamentals Snapshot

Annual Revenue: $1M
Last Q Revenue: $377,358
P/E Ratio: —
P/S Ratio: 23.9x
EPS (TTM): $-0.19
Dividend Yield: —

Why Investors Own BYSI

✓High-growth profile — revenue up +15.6% YoY with expanding US Equity exposure.
✓Healthy economics — 40% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$1M▲ +16.6% YoY

Gross Margin (TTM)

40.0%▲ +4.5% YoY

Operating Income (TTM)

$316,831▲ +16.6% YoY

Free Cash Flow (TTM)

$138,699▲ +16.6% YoY

About BEYONDSPRING INC

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.

🦦